1	Computable Phenotypes for Respiratory Viral Infections in the All of Us
2	Research Program
3	
4	Bennett J Waxse, MD, PhD ^{1,2} ; Fausto Andres Bustos Carrillo, PhD ¹ , MA, MS; Tam C
5	Tran, MS; Huan Mo, MD, MS ¹ ; Emily E Ricotta, PhD, MSc ³ ; Joshua C Denny, MD,
6	MS ^{1,4}
7	
8	Affiliations:
9	1 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD,
10	USA
11	2 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
12	MD, USA
13	3 Department of Preventive Medicine and Biostatistics, Uniformed Services University of the
14	Health Sciences, Bethesda, MD, USA
15	4 All of Us Research Program, National Institutes of Health, Bethesda, MD, USA
16	
17	Corresponding author:
18	Josh Denny, MD, MS
19	joshua.denny@nih.gov
20	240-743-1138
21	
22	Keywords: Electronic Health Records; Phenotype; Respiratory Tract Infections;
23	Reproducibility of Results; Precision Medicine
24	

25 ABSTRACT

- 26 Electronic health records (EHRs) contain rich temporal data about infectious diseases, but an
- 27 optimal approach to identify infections remains undefined. Using the *All of Us* Research
- 28 Program, we developed computable phenotypes for respiratory viruses by integrating billing
- 29 codes, prescriptions, and laboratory results within 90-day episodes. Phenotypes computed from
- 30 265,222 participants yielded cohorts ranging from 238 (adenovirus) to 28,729 (SARS-CoV-2)
- 31 cases. Virus-specific billing codes showed varied sensitivity (8-67%) and high positive predictive
- 32 value (90-97%), except for influenza virus and SARS-CoV-2 where lower PPV (69-70%)
- 33 improved with increasing billing codes. Identified infections exhibited expected seasonal
- 34 patterns and virus proportions when compared with CDC data. This integrated approach
- 35 identified episodic disease more effectively than individual components alone and demonstrated
- 36 utility in identifying severe infections. The method enables large-scale studies of host genetics,

37 health disparities, and clinical outcomes across episodic diseases.

38 INTRODUCTION

39 Respiratory infections are among the most common human diseases. Severity is influenced by

- 40 demographics, social determinants of health, comorbidities, immunosuppression, lifestyle,
- 41 exposures, and genetic factors.¹ Influenza virus, respiratory syncytial virus (RSV), and SARS-
- 42 CoV-2 are well-studied causes of lower respiratory tract infections, but over 25 known viruses
- 43 can cause such disease.² The advent of multiplex testing has revealed that rhinovirus (RV),
- 44 human metapneumovirus (hMPV), parainfluenza viruses (PIV), and common human
- 45 coronaviruses (hCoVs) can cause similar symptoms, detection rates, morbidity, mortality, and
- 46 healthcare costs in hospitalized patients.^{3–5}

47

48 Risk factors for severe infection by influenza virus, RSV, and SARS-CoV-2 are well

49 characterized. These include age extremes, immunosuppression, male sex, smoking, and

50 comorbidities such as obesity, chronic lung disease, hypertension, diabetes, and heart

51 failure.^{1,6–8} Similarly, population-level genetic risk factors have been identified through genome-

52 wide studies for SARS-CoV-2, avian influenza virus (H7N9), pandemic influenza virus

53 (H1N1_{pdm09}), and influenza virus by survey report.^{9–14} While underrecognized viruses share

54 similar risk factors like advanced age and immunocompromised status, they remain

55 understudied.^{3,4,15,16}

56

57 Population-level studies of respiratory infections typically rely on administrative claims data, 58 laboratory surveillance data, or curated clinical cohorts.^{15,17} While laboratory results and some 59 pathogen-specific billing codes are highly specific, they have poor sensitivity due to infrequent 60 testing, and adding non-specific International Classification of Diseases (ICD) codes only 61 modestly improves sensitivity.^{18,19} In contrast, electronic health record (EHR)-based 62 phenotyping algorithms can integrate multiple data types to reliably identify disease cohorts for 63 observational studies. Although integrating billing codes, clinical notes, and medications in

disease phenotyping using EHRs improves performance, this approach has only rarely been
 used for respiratory viruses.^{15,20–23}

66

This study aimed to create and assess a computable phenotype for identifying viral respiratory infections in EHR data using the National Institutes of Health's *All of Us* Research Program (*All of Us*). We evaluated ICD billing codes, medications, and laboratory results to identify infections, and assessed phenotype performance through specificity, positive predictive value (PPV) and sensitivity calculations compared to gold-standard laboratory testing; and compared the frequency and distribution of laboratory results against CDC surveillance data.

73

74 MATERIALS AND METHODS

75 Data Acquisition

76 We analyzed data from the All of Us Research Program, which digitally enrolls participants aged 18 years and older across the United States.²⁴ All of Us is a large, diverse national cohort where 77 78 participants contribute survey data, standardized physical measurements, biospecimens, and 79 EHR data including billing codes, prescriptions, and laboratory results [23]. Participants provide 80 consent to share health information, which includes physical measurements, surveys, genomic 81 data, and EHRs. The informed consent and enrollment process has been described, and 82 specific Institutional Review Board approval is not required for Controlled Tier use of de-83 identified data, deemed nonhuman subjects research by the All of Us Institutional Review 84 Board.^{24,25} The program prioritizes recruitment of populations historically underrepresented in biomedical research.²⁴ This analysis used Controlled Tier data (C2022Q4R13) from the All of Us 85 86 Researcher Workbench and was restricted to the 265,222 participants who had ICD codes, 87 medications, or laboratory results in their EHR data between 1/1/1981 and 7/1/2022. Data 88 linkage, follow-up completeness, quality assessment, privacy, and community engagement are

described in the *All of Us* Protocol.²⁶ This study meets all five of the CODE-EHR minimum
framework standards for the use of structured health care data in clinical research, with one out
of five standards meeting preferred criteria.²⁷ Participants' demographic data were derived from
the *All of Us* Researcher Workspace's "person" table and its "The Basics" survey.

93

94 Phenotype Development

95 We developed computable phenotypes for eight respiratory viruses: rhinovirus (RV); human 96 metapneumovirus (hMPV): respiratory syncytial virus (RSV): adenovirus (ADV): SARS-CoV-2. 97 parainfluenza (PIV); common human coronavirus (hCoV); and influenza virus. Patient 98 encounters were identified in the EHR if they had at least one of the following: a virus-specific 99 billing code (ICD-9-CM or ICD-10-CM), an antiviral indicated for the target pathogen, or a 100 positive laboratory test. We identified virus-specific billing codes and Logical Observation 101 Identifiers Names and Codes (LOINC) laboratory results by searching for the virus name and 102 related terms (e.g., "adenovirus" and "adenoviral pneumonia"). We excluded codes and results 103 for zoonotic infections, vaccine-related events, and ICD codes for explicitly non-respiratory 104 conditions (e.g., "ovine adenovirus", "enteritis due to adenovirus"). We also excluded codes and 105 results for pathogens sharing components of the virus name (e.g., "Haemophilus influenzae"). 106 Laboratory data included nucleic acid amplification, antigen, and culture results. For influenza 107 virus and SARS-CoV-2, we included antiviral medications (i.e., oseltamivir, zanamivir, and 108 baloxavir for influenza virus; remdesivir, molnupiravir, and nirmatrelvir/ritonavir for SARS-CoV-2) 109 given for more than one day. For oseltamivir and zanamivir, prescriptions were removed if the 110 duration of treatment was greater than 6 days to exclude prophylaxis. Antivirals for other 111 respiratory viruses were not included due to poor specificity or their reserved use for severe or 112 immunocompromised cases (Figure 1A).

114 We computed phenotypes for each infection episode by grouping related clinical events (Figure 115 1A). An episode began with the first occurrence (t_0) of any virus-specific component: a virus-116 specific ICD code, positive laboratory result, or gualifying antiviral prescription. All subsequent 117 components within 90 days of to were considered part of the same episode, while events beyond 90 days initiated new episodes.¹⁵ To capture false negatives, we included negative or 118 119 indeterminate laboratory results from t₀-5 days through the episode's end. The per-episode 120 occurrence of constituent components (ICD codes, positive laboratory results, and medications) 121 were tallied (Figure 1B). Counts for all virus-specific ICD codes, laboratory results, and 122 medications used for phenotyping are provided (Tables S1-3). We de-duplicated row-level 123 entries: categorized visit types into major categories (*i.e.*, intensive care unit, inpatient, 124 emergency room, urgent care, post-acute care, outpatient, and unknown); and reclassified 125 laboratory results as positive, negative, or indeterminate (Table S4). 126 127 **Phenotype Sensitivity Analyses** 128 Positive Predictive Value, Specificity, and Sensitivity Calculations

129 Using non-antigen test results as reference standard, we calculated the performance (PPV,

130 sensitivity, and specificity) based on increasing counts of virus-specific ICD codes within each

episode (e.g., multiple occurrences of J10.1, or combinations like J10.1 + J11 + 487). For a

given threshold N (n = 0, n ≥ 1, n ≥ 2, n ≥ 3, n ≥ 4), we defined true positives as episodes with N

virus-specific ICD codes and a positive test, false positives as episodes with *N* ICD codes and
only negative tests, and false negatives as episodes with fewer than *N* ICD codes and a positive
test.

136

For influenza virus and SARS-CoV-2, we additionally tested the performance of incorporating
antiviral prescriptions. We first assessed specificity, sensitivity, and PPV in cases requiring both

the specified ICD count and a prescription to be considered positive, or fewer than *N* ICD codes
and no prescription to be considered negative. Then, we evaluated full performance metrics
(sensitivity, specificity, PPV, negative predictive value (NPV), and phi coefficient) across
different combinations of ICD code thresholds and medication criteria for these two viruses.

144 Temporal and Geographic Analysis of Phenotype-Positive Episodes

For any episode that met positivity criteria, we analyzed temporal patterns by calculating threeweek moving averages of episode and constituent component counts from July 2017 (MMWR week 201726) through June 2022 (MMWR week 202225). Because hCoV PPV was lower than expected for non-influenza, non-SARS-CoV-2 viruses, and as hCoV ICD counts were disrupted during the COVID-19 pandemic, hCoV ICD codes after February 1, 2020 were excluded from the analysis (Figure S3). We assessed the geographic distribution of episode rates by threedigit ZIP code prefixes (zip3).

152

153 Level of Care Sensitivity Analysis

154 Because of differences in testing and care by facility type and acuity, for each episode we 155 identified the highest acuity encounter (from lowest to highest: outpatient, post-acute care, 156 urgent care, emergency department, or inpatient) within a window spanning to-7 days through 157 t_0 +14 days. We chose this window after analyzing the distributions of visit timing for phenotype-158 related visits (those associated with virus-specific ICD codes, antivirals, or laboratory results) 159 and all visits (Figure S4). Use of all visits within the selected window, rather than only 160 phenotype-related visits, reduced the overall percentage of missing encounter data from 25.9% 161 to 15.4%; across viruses and ICD counts, median missing encounter data decreased from 162 17.6% (IQR 7.6-28.3%) to 11.3% (IQR 2.2-17.8%) (Table S5). Rarely (0.09%-0.43%), 163 phenotype-related maximum encounter acuity exceeded encounters within this time window 164 (e.g., hospitalization occurring >7 days prior to initial viral diagnosis, Figure S5). For PIV, hMPV,

and RSV, manual review of these visits revealed that the associated encounter start date

166 preceded the window period by a few days, and the phenotype component level of care was

167 retained. We analyzed level-of-care patterns across viruses, stratifying by ICD codes and test

168 positivity.

169

170 Comparison with National Surveillance Data

171 To understand the representativeness of respiratory illness data in All of Us, we compared the

seasonal percent positivity and test volume of *All of Us* EHR laboratory results to data from

173 three CDC/WHO sources: National Respiratory and Enteric Virus Surveillance System

174 (NREVSS), COVID-19 Data Tracker, and the Global Influenza Surveillance and Response

175 System (GISRS).

176

177 First, we assessed geographic coverage by comparing All of Us participant locations and testing rates to deduplicated NREVSS clinical laboratory results from 2017-2021.²⁸ All of Us EHR 178 179 participant counts were visualized by aggregating data across three-digit ZIP code prefixes 180 (zip3). Zip3 information was missing for 2/265,222 (0.00%). All of Us EHR participants (per 181 1,000 zip3 2020 Census population) and All of Us participants tested (per 1,000 All of Us 182 participants with EHR data) were similarly aggregated by zip3 code. Zip3 regions with five or 183 fewer All of Us participants were removed and classified as "No Data." We obtained zip3 184 boundaries from US Census Bureau zip code tabulation areas, 2017 cartographic state 185 boundaries from the Vega us-10m ison dataset, and 2020 zip code tabulation area populations 186 from the US Census Bureau.

187

Next, we assessed virus distribution by comparing proportions detected (% = N type / N total with known type) in *All of Us* to surveillance data from NREVSS and the GISRS.^{29–31} These

- 190 comparisons were limited to hCoV, influenza virus, and PIV, as these were the only viruses for
- 191 which syndromic multiplex panels routinely report type-specific results.
- 192
- 193 To evaluate temporal patterns, we compared weekly test positivity data between All of Us and
- 194 CDC surveillance from the first week of July, 2016 to the last week of June, 2022. For each
- 195 virus, we calculated the percentage of positive tests for each *MMWR* reporting week. We plotted
- 196 three-week moving averages for both percent positivity and total tests performed for *All of Us*
- and CDC data. We obtained CDC comparison data from NREVSS for non-SARS-CoV-2
- 198 viruses, additional influenza virus data from FluView, and SARS-CoV-2 data from the COVID
- 199 Data Tracker.^{28,32,33}
- 200
- 201 **RESULTS**
- 202 Cohort Characteristics
- 203 Among 265,222 All of Us participants with ICD codes, medication entries, or laboratory results
- recorded between 1/1/1981 and 7/1/2022, we identified respiratory virus episodes that varied
- substantially in duration and composition (Figure 1B). SARS-CoV-2 (n [distinct
- episodes]=28,729) and influenza virus (n=19,784) were the largest cohorts, followed by RV
- 207 (n=1,620), hCoV (n=1,437), and RSV (n=1,161) and the smallest cohorts, hMPV (n=486), PIV
 208 (n=400), and ADV (n=238).
- 209

Across all cohorts, participants were predominantly female (61-68%) with median ages mostly between 50 and 58 (Table S6). Participants who self-reported as White were the plurality for every virus (32.9-60.1%), compared to participants self-reporting as Black (16.5-28.5%) or Hispanic/Latino (17-32.1%). All other options (Asian, multiple selected, Middle Eastern or North African, and Native Hawaiian or Other Pacific Islander) were rare (0-2.2%). SARS-CoV-2 and influenza virus participant demographics most closely mirrored the overall *All of Us* cohort with

ICD, laboratory, or medication data. These two groups more frequently self-reported as White
(50.4-60.1%) and were more frequently employed with higher reported income, education, and
employer-provided insurance. Demographic data were only notably missing for insurance type
(46,487/265,222=17.5% for all participants with EHR data). Test count per person was higher
among infected cohorts than tested cohorts for each virus.
Episodes commonly consisted of either laboratory results alone (predominant for RV [74.7%],

PIV [65.0%], SARS-CoV-2 [31.3%], hMPV [32.9%]) or single ICD codes (predominant for ADV

224 [45.8%], hCoV [43.1%], RSV [35.4%], influenza [34.8%]) (Figure 1B). Antiviral use varied

225 markedly: SARS-CoV-2 episodes rarely included antiviral prescriptions (4.57%), while

226 medication-only episodes were frequently observed for influenza virus (22.9%), even after

227 excluding prophylactic prescriptions.

228

229 Phenotype Performance for Detecting True Positives

230 To understand the diagnostic performance of varying ICD codes for an episode, we calculated

sensitivity, specificity, and PPV for each virus across N ICD codes per episode using non-

antigen test results as a reference standard (Figure 2). The sensitivity of using one or more ICD

233 codes varied between viruses and decreased as the minimum *N* ICD codes increased.

Diagnoses using one or more ICD codes for influenza virus had the highest sensitivity (66.8%),

compared to moderate sensitivity for RSV (55.2%), SARS-CoV-2 (44.8%), ADV (42.4%), hMPV

236 (40.2%), and hCoV (33.4%), and minimal sensitivity for RV (9.2%) and PIV (8.3%).

237

238 Specificity and PPV demonstrated similar patterns, with exaggerated variation in PPV initially

239 demonstrating three groupings. First, for influenza virus and SARS-CoV-2, the PPV for one or

240 more ICD codes was lower (69.7% and 68.8%, respectively), but increased as minimum N ICD

count increased (78.1% and 76.7% for at least 2 ICD codes, respectively) (Figure 2). Second,

242	for non-influenza, non-SARS-CoV-2 viruses, the PPV was high and did not change substantially
243	as ICD count increased (89.7-97.3%). Third, hCoV initially demonstrated a high PPV (79.5%)
244	that decreased as ICD count increased (71.8% for at least 2 ICD codes) (Figure S3A).
245	
246	During the COVID-19 pandemic, hCoV ICD code counts spiked above historical maxima despite
247	an absence of positive tests (Figure S3B). After removing hCoV ICD codes after February 1,
248	2020, the PPV trend for common hCoV became similar to other non-influenza, non-SARS-CoV-
249	2 viruses (Figure 2, Figure S3A).
250	
251	Adding medication use to the phenotype had varying effects on performance. As with the
252	medication-exclusive phenotypes, specificity and PPV increased with each additional ICD code
253	for the medication-inclusive influenza and SARS-CoV-2 cohorts. While only a small proportion
254	(1,345/28,741=4.67%) of SARS-CoV-2 episodes included a prescription for remdesivir,
255	molnupiravir or nirmatrelvir, the addition of medication to the phenotype did increase PPV for
256	this subset of 1,345 participants (Figure 2). For influenza virus, medication use alone was poorly
257	predictive (PPV=46.8%), but combining medications with 1 ICD code improved PPV compared
258	to 1 or more codes alone (87.1% vs. 69.7%, respectively) (Figure 2).
259	
260	Varying ICD code thresholds and antiviral requirements in the entire influenza and SARS-CoV-2

cohorts demonstrated an expected trade-off in performance (Table 1). For both viruses, at least
one ICD code or medication was the most sensitive phenotype (76.0% influenza virus and
45.1% SARS-CoV-2), but this caused the highest number of false positives and the lowest
PPVs (65.8% and 68.8%, respectively). For influenza virus, by requiring at least two ICD codes
or a medication accompanied by an ICD code, the lower sensitivity (47.7%) was accompanied
by a marked reduction in false positives (778 to 238) and increase in PPV (65.8% to 79.8%).

- 267 Similar trends were observed for SARS-CoV-2, and despite trade-offs, the phi coefficient was
- 268 highest for the broadest phenotypes.
- 269

Table 1 Phenotype Performance

			Coun	ts (N)			Phenot	ype Perfor	mance	
	Phenotype	TP	FP	FN	TN	Sen.	Spec.	PPV	NPV	φ
Flu	1+ ICDs or medication	1496	778	472	32018	0.760	0.976	0.658	0.985	0.688
	1+ ICDs	1315	572	653	32224	0.668	0.983	0.697	0.980	0.664
	2+ ICDs or medication	1120	444	848	32352	0.569	0.986	0.716	0.974	0.619
	2+ ICDs or (1 ICD + medication)	939	238	1029	32558	0.477	0.993	0.798	0.969	0.600
	3+ ICDs or medication	941	339	1027	32457	0.478	0.990	0.735	0.969	0.574
	3+ ICDs or (1-2 ICDs + medication)	760	133	1208	32663	0.386	0.996	0.851	0.964	0.558
	2+ ICDs	691	194	1277	32602	0.351	0.994	0.781	0.962	0.506
	3+ ICDs	360	68	1608	32728	0.183	0.998	0.841	0.953	0.379
	1+ ICDs or medication	7298	3302	8894	177219	0.451	0.982	0.688	0.952	0.526
	1+ ICDs	7258	3298	8934	177223	0.448	0.982	0.688	0.952	0.524
	2+ ICDs or medication	4483	1324	11709	179197	0.277	0.993	0.772	0.939	0.438
COVID	2+ ICDs or (1 ICD + medication)	4443	1320	11749	179201	0.274	0.993	0.771	0.938	0.435
	3+ ICDs or medication	2598	546	13594	179975	0.160	0.997	0.826	0.930	0.345
	3+ ICDs or (1-2 ICDs + medication)	2558	542	13634	179979	0.158	0.997	0.825	0.930	0.342
	2+ ICDs	4309	1310	11883	179211	0.266	0.993	0.767	0.938	0.427
	3+ ICDs	2260	523	13932	179998	0.140	0.997	0.812	0.928	0.318

TP: true positive; FP: false positive; FN: false negative; TN: true negative; Sen: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; φ: phi coefficient (mean square contingency coefficient).

271 We identified infection episodes nationwide, with SARS-CoV-2 and influenza virus

272 demonstrating the broadest US coverage. While episodes generally matched the All of Us EHR

273 subgroup distribution (Figure S1C), incorporating ICD codes and medications exhibited higher

274 infection rates in the Southeast and Texas despite lower testing coverage in these regions

275 (Figure 3). Temporally, episodes composed of 1-3 ICD codes showed seasonality patterns

consistent with test-positive episodes for all frequently detected viruses (Figure 4). During the

early COVID-19 pandemic (winter 2020 to spring 2021), only SARS-CoV-2 and RV were

278 consistently identified.

²⁷⁰

279	
280	Patterns in Phenotype Composition by Level of Care
281	Encounter level of care varied by virus and episode composition. For RV, hMPV, PIV, hCoV,
282	and SARS-CoV-2, episodes defined by at least one test without ICD codes were the most
283	frequent, while for RSV, ADV, and influenza virus, ICD-only episodes predominated (Figure 5).
284	Influenza virus episodes with antiviral prescriptions showed a similar distribution of visit types
285	compared to those without, while SARS-CoV-2 episodes rarely included prescriptions during our
286	study period.
287	
288	By percentage, influenza virus and SARS-CoV-2 episodes showed a mix of outpatient, ER, and
289	inpatient encounters, while other viruses demonstrated higher rates of ER visits and
290	hospitalization. Episodes containing a positive test consistently showed higher rates of
291	hospitalization compared to test-negative episodes. Similarly, hospitalization rates increased as
292	the number of ICD codes within an episode increased. The cohorts included very few post-acute
293	care encounters and almost no urgent care encounters.
294	
295	Laboratory Result Comparison
296	Using national epidemiological data from NREVSS, COVID Data Tracker, and GISRS, we
297	compared All of Us laboratory results by geographic coverage, virus type proportion, and
298	temporal trends.
299	
300	We found broad US coverage of All of Us participants with relevant EHR data (265,222
301	participants), with enriched sampling near population centers in the Northeast megalopolis;
302	Western Pennsylvania; Great Lakes Region; Southeast; Arizona; California; and the
303	metropolitan areas of Austin/Dallas, Kansas City, Denver, and Seattle (Figure S1A, Table S7).
304	Only 3.7% of zip3 codes had no All of Us participants with ICD, laboratory, or medication data.

306	Testing patterns in the All of Us data overlapped with CDC clinical laboratories reporting to
307	NREVSS (Figure S1B) and mirrored participant distribution (Figure S1A) with a notable
308	decrease in testing for all respiratory viruses in the Southeast relative to participant density
309	(Figure S1C). Testing frequency varied substantially by virus; participants were more frequently
310	tested for influenza virus and SARS-CoV-2 compared to all other viruses.
311	
312	Virus type distributions in All of Us were similar to national surveillance data from NREVSS and
313	GISRS. ^{29–31} For PIV (2011-2019), HPIV-3 was most commonly detected and all other types
314	were less frequent (Figure S2A). For hCoV (2014-2021), OC43 was most common and 229E
315	was least common, while the order of NL63 and HKU1 differed (Figure S2B). Influenza virus
316	type proportions (2010-2020) were nearly identical, with influenza virus A more common than
317	influenza virus B (Figure S2C). Cross-dataset influenza subtype comparisons were not
318	available, but in All of Us, H3N2 and H1N1 pdm09 were markedly more common than H1N1
319	and H5N1, as expected.
320	
321	Test positivity patterns from 2017 to 2022 matched CDC rates for most viruses (mean absolute
322	error 5.89 percent positive tests per week for RV and 1.18-2.82 for all other viruses) (Figure 6).
323	SARS-CoV-2, influenza virus, and RV showed the highest percent positivity, and most viruses
324	showed expected seasonal patterns: PIV and RV exhibited two seasonal peaks per year
325	(spring-dominant for PIV, fall-dominant for RV), while RSV, influenza, and hMPV demonstrated
326	single overlapping winter peaks. SARS-CoV-2 positivity matched expected variant waves (e.g.,
327	Alpha, Delta, and Omicron BA.1). Notable differences in the All of Us data include more
328	variability in RSV tests and positivity, undercounted positivity by ~10% during peak respiratory
329	season for influenza and RSV, and less ADV positivity, relative to CDC data.
330	

331 **DISCUSSION**

This study demonstrates that combining virus-specific EHR data elements reliably identifies respiratory viral infections in large biobank datasets. Using temporal, geographic, and sensitivity analyses, we described important performance insights into respiratory virus phenotyping. All phenotypes exhibited high specificity, though trade-offs exist between accuracy and sensitivity for influenza virus and SARS-CoV-2.

337

338 We identified epidemiological patterns and cohort sizes that matched national surveillance data. 339 The combination of laboratory results, ICD codes, and medications increased case detection 340 beyond what any component alone could identify, which was valuable where laboratory testing 341 was less frequent (e.g., the Southeast). The cohorts varied in size: approximately 20,000-342 30,000 episodes for influenza virus and SARS-CoV-2 compared to 200-1,600 for other viruses. 343 likely reflecting increased clinical suspicion and testing for common pathogens rather than true differences in disease burden.¹⁵ These cohorts could be used to investigate host genetic 344 345 factors, health disparities, geographic and environmental risk factors, and clinical outcomes 346 across respiratory viral infections. The longitudinal available also supports study of lifestyle 347 factors through wearables and patient-reported outcomes from surveys.

348

349 Phenotype performance varied substantially between viruses, across episode composition, and 350 over time. Virus-specific ICD code sensitivity varied widely: higher for influenza (66.8% vs. 38-351 95% in published studies) and RSV (55.2% vs. 24%) and moderate for SARS-CoV-2, ADV, 352 hMPV, and hCoV (33-44%), but very low for PIV (8.3% vs. 14% and RV (9.2% vs. 0%).^{18,19,34-36} 353 While non-influenza, non-SARS-CoV-2 virus-specific ICD codes showed high PPV regardless of 354 count (89.7-97.3%), single ICD codes for SARS-CoV-2 and influenza were less predictive (68.8-69.7%).^{18,19,35,36} For medication-inclusive cases, ICD codes had a higher PPV for influenza virus 355 356 and SARS-CoV-2 episodes, and for SARS-CoV-2, antivirals alone were highly predictive of test

results, although receipt of remdesivir, molnupiravir or nirmatrelvir was rare (4.57% of all
episodes) during the study period.

359

360 The COVID-19 pandemic disrupted the seasonal transmission of most respiratory viruses, 361 granting the opportunity to assess ICD code performance in unexpected settings and 362 demonstrating the importance of evaluating code performance over time for seasonally variable 363 diseases. hCoV ICD codes were inappropriately used to identify concern for COVID-19 364 infection, with diminished but persistent effects throughout the study period. Apart from 365 rhinovirus, our phenotypes only rarely identified false positive episodes during the COVID-19 366 pandemic, mostly attributable to influenza virus episodes composed of a single ICD code. We 367 suspect that these episodes reflect clinical concern for infection rather than true infection, and 368 indeed, adjusting the influenza phenotype from any ICD code or medication to 2+ ICD codes or 369 medications accompanied by an ICD code markedly reduced false positives and increased 370 PPV. In this work, we suggest choosing phenotype characteristics that match the research 371 question and desire to maximize sensitivity vs. PPV.

372

373 Level-of-care analyses revealed patterns suggesting systematic detection biases toward higher 374 acuity settings. Our phenotype identified a high frequency of infections at emergency and 375 inpatient visits for RV, hMPV, RSV, ADV, PIV, and hCoV, compared to more outpatient visit 376 types for SARS-CoV-2 and influenza virus. These findings differ from established hospitalization 377 rates: CDC estimates suggest that only 1-2% of medically-attended influenza cases require 378 hospitalization, while COVID-19 hospitalization rates ranged between 2.1% and 68% over this 379 study period, with temporal trends showing a decrease from \sim 50% in the early pandemic to 20% by July, 2022.^{37–41} Moreover, prospective studies in adults have shown that other respiratory 380 381 viruses show either similar or lower hospitalization rates compared to influenza - the opposite of our results.^{4,16} This discordance suggests that the *All of Us* computable phenotype oversamples 382

high levels of care, particularly for non-influenza, non-SARS-CoV-2 viruses, likely due at least
three factors: the lack of cost-effective outpatient assays, an absence of specific therapeutic
interventions that would justify multiplex testing costs in lower-acuity care settings, and the utility
of identifying an etiology in the inpatient setting, where cessation of antibiotics or discharge are
considerations.

388

389 Several limitations affect the interpretation and generalizability of these findings. The low

390 sensitivity for all viruses indicates that this method cannot be used to study disease prevalence,

as nonspecific syndromic coding likely predominates for upper respiratory illnesses.

392 Additionally, the requirement for data conversion to a common data model before release in

393 curated data repositories means this method cannot support real-time surveillance. In addition,

394 while All of Us provides broad national coverage, it highly sampled some states (AZ, MA, WI,

395 AL, PA, IL, MI, NY, MS, CA) and left approximately half the US population sampled below rates

396 of 1 in 10,000. The program's intentional oversampling of populations historically

397 underrepresented in biomedical research, while invaluable to health equity research, also

398 results in demographics that differ from the overall US population. Other known impediments to

399 generalizability compared to the US population include decreased representation of blind and

400 deaf participants; difficulty in linking EHRs from a considerable portion of *All of Us* participants;

401 and the decreased representation of persons of Asian, Middle Eastern or North African, and

402 Native Hawaiian or Other Pacific Islander heritage in this cohort.⁴²

403

Finally, this work faces challenges common to EHR-based research. These include labeling
bias, implicit clinician biases which could be influenced by demographics, and informed
presence bias where EHR inclusion typically reflects illness rather than routine care.^{43,44} The
minimal representation of urgent care and post-acute care in our data further underscore the

disconnected nature of healthcare in the US, and identifies a likely gap in infection detection inthis cohort.

410

- 411 Despite these limitations, our computable phenotypes reliably detected geographic and
- 412 temporal patterns of infection matching national surveillance, although severe infections are
- 413 oversampled and many mild infections are likely missed. This work supports a need for
- 414 expanded surveillance of non-influenza/non-SARS-CoV-2 pathogens in routine medical care.⁴⁵
- 415 Using a cohort that is expected to continually grow, our results enable future studies of genetic
- 416 susceptibility and clinical outcomes research across both well-studied and understudied
- 417 respiratory viruses. This work serves as a foundation for the creation and validation of other
- 418 computable phenotypes for episodic infectious diseases using EHR-based methods.

419

- 420 DATA AND CODE AVAILABILITY
- 421 The Community Workspace "Respiratory Virus Computable Phenotype" is available for all
- 422 approved *All of Us* users and includes all code and data used in this work
- 423 (https://workbench.researchallofus.org/workspaces/aou-rw-
- 424 ae307fda/respiratoryviralinfectionsinallofus/analysis).
- 425

426 ACKNOWLEDGEMENTS

- 427 S Olsen and A Winn (CDC) kindly provided percent positivity data and locations of CDC clinical
- 428 labs reporting to NREVSS. This work received an exception to the Data and Statistics
- 429 Dissemination Policy from the All of Us Resource Access Board for figures 4 and 5. The primary
- 430 author acknowledges the use of Claude (Anthropic) in the generation and revision of code to
- 431 produce this computable phenotype, and in the revisions of this manuscript.
- 432

433 The contents of this publication are the sole responsibility of the authors. The content of this 434 publication does not necessarily reflect the views, opinions, or policies of the NIH, the 435 Uniformed Services University of the Health Sciences, the US Department of Health and Human 436 Services, the US Department of Defense, or the US Government, nor does mention of trade 437 names, commercial products, or organizations imply endorsement by the US government. This 438 work was prepared by a military or civilian employee of the US Government as part of the 439 individual's official duties. Therefore, it is in the public domain and does not possess copyright 440 protection. Public domain information may be freely distributed and copied; however, as a 441 courtesy, it is requested that the authors be given an appropriate acknowledgement. 442 443 This work was supported by the National Human Genome Research Program Intramural 444 Research Program, grant numbers: ZIA HG200417, ZIC HG200420; and the Division of 445 Intramural Research of the National Institute of Allergy and Infectious Diseases. The All of Us 446 Research Program is supported by the National Institutes of Health, Office of the Director: 447 Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 448 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 449 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 450 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; 451 The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 452 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and 453 Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 454 OD025276. Funders played no role in study design, data collection, analysis and interpretation 455 of data, or the writing of this manuscript.

457 AUTHOR CONTRIBUTIONS

- 458 BJW and JCD conceived of the study design. BJW constructed the phenotype, conducted all
- 459 analyses, and drafted the manuscript. TCT and HM contributed foundational data analysis
- 460 support. FABC and EER offered appraisal of data analysis and early revision of the manuscript.
- 461 All authors contributed to the final revision of the manuscript.

462

463 COMPETING INTERESTS

464 All authors declare no financial or non-financial competing interests.

466 FIGURES AND FIGURE LEGENDS

a Phenotype Definition



b Episode Proportion by Component

SARS-CoV-2	0.25	0.09	0.06	0.31	0.10	0.07	0.07	28729	0.01	0.01	0.01	0.00	0.00	0.02	- 100
- Fi	0.35	0.10	0.04	0.03	0.03	0.01	0.01	19784	0.23	0.08	0.06	0.01	0.02	0.03	- 80
RV -	0.15	0.02	0.01	0.75	0.04	0.01	0.01	1620	N/A	N/A	N/A	N/A	N/A	N/A	- 60
hCoV I	0.43	0.18	0.09	0.20	0.06	0.02	0.02	1437	N/A	N/A	N/A	N/A	N/A	N/A	
RSV	0.35	0.15	0.14	0.16	0.09	0.04	0.07	1161	N/A	N/A	N/A	N/A	N/A	N/A	- 40
hMPV I	0.31	0.08	0.04- 0.06	0.33	0.12	<0.04	0.07	486	N/A	N/A	N/A	N/A	N/A	N/A	- 20
PIV -	0.20	<0.04	<0.04	0.65	<0.04	<0.01	<0.01	400	N/A	N/A	N/A	N/A	N/A	N/A	
ADV -	0.46	<0.07	0.08	0.22	0.08	<0.03	<0.05	238	N/A	N/A	N/A	N/A	N/A	N/A	
	1 ICD only –	2 ICDs only –	3+ ICDs only -	1+ labs only -	1+ labs & 1 ICD –	1+ labs & 2 ICDs –	1+ labs & 3+ ICDs –	episodes -	1+ treatments only -	treatments & 1 ICD –	eatments & 2+ ICDs –	ıbs & 1+ treatments –	treatments & 1 ICD –	eatments & 2+ ICDs –	

467

468 **Figure 1.** Computational phenotype for respiratory virus episodes using electronic health

469 records (EHRs) with respiratory episode composition. A: Episodes were defined by (1) virus-

470 specific ICD-9-CM or ICD-10-CM codes, (2) antiviral medications (for influenza and SARS-CoV-

471 2), and/or (3) positive laboratory results including nucleic acid amplification tests (NAAT). 472 antigen tests, or cultures. The first qualifying event is designated as time zero (t_0), and all 473 related, subsequent events within 90 days were grouped into the same episode. Negative or 474 indeterminate tests were also included, with a five-day lookback window to incorporate false 475 negative results. Phenotypes were computed for influenza, human metapneumovirus (hMPV), 476 respiratory syncytial virus (RSV), parainfluenza, rhinovirus (RV), SARS-CoV-2, common human 477 coronavirus (hCoV), and adenovirus (ADV). Heatmap (B) showing the breakdown of episode 478 types (columns) for each virus (row). Colors indicate the percentage of counts for each virus 479 (e.g., 74.9% of RV episodes (1,210/1,620) contained only positive laboratory results. 480 Percentage and corresponding color for counts below 20 (with a second count to prevent back-481 calculation for hMPV), were censored per the All of Us participant privacy policy. N/A : not

482 applicable.









b All of Us Respiratory Infection Episodes (per 1000 Participants)



495

Figure 3. Geographic distribution of respiratory virus episodes. Heat maps show episode rates per 1,000 *All of Us* participants with EHR data by three-digit zip code prefix. Colors represent quintiles defined by SARS-CoV-2 rates, the largest cohort. Regions with five or fewer *All of Us* participants are marked as "No Data" in (B). *Human coronavirus episodes were filtered as described in methods. RSV: respiratory syncytial virus.



502

Figure 4. Temporal patterns of respiratory virus episodes by composition. Three-week moving
averages shown for (A) parainfluenza, (B) human metapneumovirus, (C) rhinovirus, (D)
adenovirus, (E) respiratory syncytial virus (RSV), (F) human coronavirus, (G) influenza virus,
and (H) SARS-CoV-2. For each virus, lines show total episodes (gray) and episodes by
composition: one or more positive tests (blue), single ICD code (light orange), two ICD codes

- 508 (light green), and three or more ICD codes (red-orange). For influenza, and SARS-CoV-2,
- additional lines show episodes with antiviral prescriptions alone (dark green) or with concurrent
- 510 ICD codes (pink). Gray shading indicates testing volume. Left y-axis corresponds to episode
- 511 counts; right y-axis shows total tests performed. *Episodes for hCoV are shown after applying
- 512 temporal filtering (unfiltered plot compared in Figure S3).
- 513



a Visit Type Count by Virus and ICD Code Count





515 **Figure 5.** Level of care patterns by virus and episode composition. For each virus, (A) counts

- and (B) percentages of maximum level of care recorded between seven days before and 14
- 517 days after episode start. Results are stratified by episode characteristics: episodes with positive
- tests (upper panels) versus those without (lower panels), and by number of ICD codes
- 519 (columns). Color intensity corresponds to level of care: inpatient (IP, darkest), emergency room
- 520 (ER), urgent care (UC), outpatient (OP), and unknown (lightest). For influenza virus (Flu) and
- 521 SARS-CoV-2, additional columns show episodes containing antiviral prescriptions. PIV:
- 522 parainfluenza; hMPV: human metapneumovirus; RV: rhinovirus; ADV: adenovirus; RSV:
- 523 respiratory syncytial virus; hCoV: human coronavirus; Rx: antiviral prescription.



525

Figure 6. Temporal validation of test positivity using CDC surveillance data. Three-week moving
average of test positivity and test volume comparing *All of Us* (gray) to CDC surveillance data
(blue) for eight respiratory viruses: (A) parainfluenza, (B) human metapneumovirus, (C)
rhinovirus, (D) adenovirus, (E) respiratory syncytial virus (RSV), (F) common human

530 coronavirus (hCoV), (G) influenza virus, and (H) SARS-CoV-2. In each case, percent positivity

- 531 (lines) corresponds to the left y-axis and total tests performed (shaded areas) corresponds to
- the right y-axis. CDC data were obtained from NREVSS for panels A-F (ending 2021), FluView
- 533 for influenza virus, and COVID Data Tracker for SARS-CoV-2. AoU: All of Us.
- 534

535 **REFERENCES**

- 536 1. Clementi, N. et al. Viral Respiratory Pathogens and Lung Injury. *Clin. Microbiol. Rev.*537 222, 563–569 (2019).
- 3. Boon, H., Meinders, A., Hannen, E. J. van, Tersmette, M. & Schaftenaar, E.
- 539 Comparative analysis of mortality in patients admitted with an infection with influenza
- 540 A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS-CoV-2.
- 541 Influ. Other Respir. Viruses 18, e13237 (2024).
- 542 4. Lee, N. et al. Burden of noninfluenza respiratory viral infections in adults admitted to
- 543 hospital: analysis of a multiyear Canadian surveillance cohort from 2 centres. CMAJ
- 544 193, E439–E446 (2021).
- 545 5. Korsten, K. et al. Burden of respiratory syncytial virus infection in community-dwelling
- 546 older adults in Europe (RESCEU): an international prospective cohort study. *Eur.*
- 547 *Respir. J.* 57, 2002688 (2021).
- 548 6. DeMartino, J. K. et al. Respiratory Syncytial Virus–Related Complications and
- 549 Healthcare Costs Among a Medicare-Insured Population in the United States. Open
- 550 Forum Infect. Dis. 10, ofad203 (2023).
- 551 7. Chenchula, S. et al. Global prevalence and effect of comorbidities and smoking
- status on severity and mortality of COVID-19 in association with age and gender: a
- 553 systematic review, meta-analysis and meta-regression. *Sci. Rep.* 13, 6415 (2023).

- 8. Andrew, M. K. et al. Age Differences in Comorbidities, Presenting Symptoms, and
- 555 Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From
- the Global Influenza Hospital Surveillance Network. Open Forum Infect. Dis. 10,
- 557 ofad244 (2023).
- 558 9. Lee, N. et al. IFITM3, TLR3, and CD55 Gene SNPs and Cumulative Genetic Risks for
- 559 Severe Outcomes in Chinese Patients With H7N9/H1N1pdm09 Influenza. J. Infect. Dis.
- 560 216, 97–104 (2017).
- 561 10. López-Rodríguez, M. et al. IFITM3 and severe influenza virus infection. No evidence
- of genetic association. *Eur. J. Clin. Microbiol. Infect. Dis.* 209, 1028–1031 (2014).
- 563 12. Yang, X. et al. Interferon-Inducible Transmembrane Protein 3 Genetic Variant
- rs12252 and Influenza Susceptibility and Severity: A Meta-Analysis. *PLoS ONE* 10,
- 565 e0124985 (2015).
- 566 13. Initiative, C.-19 H. G. et al. A first update on mapping the human genetic
- 567 architecture of COVID-19. *Nature* 608, E1–E10 (2022).
- 568 14. Kosmicki, J. A. et al. Genetic risk factors for COVID-19 and influenza are largely
- 569 distinct. *Nat. Genet.* 1–5 (2024) doi:10.1038/s41588-024-01844-1.
- 570 15. Hedberg, P. et al. Clinical phenotypes and outcomes of SARS-CoV-2, influenza,
- 571 RSV and seven other respiratory viruses: a retrospective study using complete hospital
- 572 data. *Thorax* . 206, 56–62 (2012).
- 573 17. Buda, S., Tolksdorf, K., Schuler, E., Kuhlen, R. & Haas, W. Establishing an ICD-10
- 574 code based SARI-surveillance in Germany description of the system and first results
- 575 from five recent influenza seasons. *BMC Public Heal.* 17, 612 (2017).
- 576 18. Cai, W. et al. Evaluation of using ICD-10 code data for respiratory syncytial virus

- 577 surveillance. Influ. Other Respir. Viruses 14, 630–637 (2020).
- 19. Hamilton, M. A. et al. Validating International Classification of Disease 10th Revision
- algorithms for identifying influenza and respiratory syncytial virus hospitalizations. *PLoS*
- 580 ONE 16, e0244746 (2021).
- 581 20. Wei, W.-Q. et al. Combining billing codes, clinical notes, and medications from
- 582 electronic health records provides superior phenotyping performance. J. Am. Med.
- 583 Inform. Assoc. 23, e20–e27 (2016).
- 21. Fathima, S., Simmonds, K., Invik, J., Scott, A. N. & Drews, S. Use of laboratory and
- administrative data to understand the potential impact of human parainfluenza virus 4
- 586 on cases of bronchiolitis, croup, and pneumonia in Alberta, Canada. BMC Infect. Dis.

587 16, 402 (2016).

- 588 22. Cocoros, N. M. et al. Early Release Electronic Health Record–Based Algorithm for
- 589 Monitoring Respiratory Virus–Like Illness Volume 30, Number 6—June 2024 -
- 590 Emerging Infectious Diseases journal *CDC. Emerg. Infect. Dis.* 30, 1096–1103 (2024).
- 591 23. Khera, R. et al. A multicenter evaluation of computable phenotyping approaches for
- 592 SARS-CoV-2 infection and COVID-19 hospitalizations. npj Digit. Med. 5, 27 (2022).
- 593 24. Investigators, A. of U. R. P. et al. The "All of Us" Research Program. *N. Engl. J.*
- 594 *Med.* 381, 668–676 (2019).
- 595 25. Office, A. of U. I. R. B. O. Not Human Subjects Research Determination: Research
- 596 Hub: Controlled Tier Data Access Process for the All of Us Research Program. (2021).
- 597 26. Investigators, A. of U. R. P. All of Us Research Program Protocol. Preprint at
- 598 https://allofus.nih.gov/sites/default/files/AOU_Core_Protocol_Redacted_Dec_2021.pdf
- 599 (2021).

- 27. Kotecha, D. et al. CODE-EHR best practice framework for the use of structured
- electronic healthcare records in clinical research. *BMJ* 378, e069048 (2022).
- 28. Olsen, S. J. et al. Changes in Influenza and Other Respiratory Virus Activity During
- the COVID-19 Pandemic United States, 2020–2021. Morb. Mortal. Wkly. Rep. 70,
- 604 1013–1019 (2021).
- 29. DeGroote, N. P. et al. Human parainfluenza virus circulation, United States, 2011–
- 606 2019. J. Clin. Virol. 124, 104261 (2020).
- 30. Shah, M. M. et al. Seasonality of Common Human Coronaviruses, United States,
- 608 2014–2021 Volume 28, Number 10—October 2022 Emerging Infectious Diseases
- 609 journal CDC. Emerg. Infect. Dis. 28, 1970–1976 (2022).
- 31. Malosh, R. E., McGovern, I. & Monto, A. S. Influenza During the 2010–2020 Decade
- in the United States: Seasonal Outbreaks and Vaccine Interventions. *Clin. Infect. Dis.*
- 612 76, 540–549 (2022).
- 32. Prevention, C. for D. C. and. Influenza (flu) weekly U.S. influenza surveillance report
- 614 (FluView). https://gis.cdc.gov/grasp/fluview/fluportaldashboard.html.
- 33. Prevention, C. for D. C. and. COVID Data Tracker. https://covid.cdc.gov/covid-data-tracker/.
- 617 34. Higgins, T. L. et al. Assessment of the Accuracy of Using ICD-9 Diagnosis Codes to
- 618 Identify Pneumonia Etiology in Patients Hospitalized With Pneumonia. JAMA Netw.
- 619 *Open* 3, e207750 (2020).
- 620 35. Sivakumaran, S., Alsallakh, M. A., Lyons, R. A., Quint, J. K. & Davies, G. A.
- 621 Estimating the contribution of respiratory pathogens to acute exacerbations of COPD
- 622 using routine data. J. Infect. 86, 233–238 (2023).

- 623 36. Alchikh, M. et al. Are we missing respiratory viral infections in infants and children?
- 624 Comparison of a hospital-based quality management system with standard of care. *Clin.*
- 625 *Microbiol. Infect.* 25, 380.e9-380.e16 (2019).
- 626 37. Services, U. D. of H. and H. & CDC. CDC. Influenza (flu): Flu Burden.
- 627 https://www.cdc.gov/flu-burden/php/about/index.html (2024).
- 38. Near, A. M., Tse, J., Young-Xu, Y., Hong, D. K. & Reyes, C. M. Burden of influenza
- hospitalization among high-risk groups in the United States. *BMC Heal. Serv. Res.* 22,
- 630 1209 (2022).
- 39. Nikolla, D. A. et al. Defining Incidental Versus Non-incidental COVID-19
- 632 Hospitalizations. *Cureus* 16, e56546 (2024).
- 40. Vu, C. et al. A More Accurate Measurement of the Burden of Coronavirus Disease
- 634 2019 Hospitalizations. Open Forum Infect. Dis. 9, ofac332 (2022).
- 41. Menachemi, N., Dixon, B. E., Wools-Kaloustian, K. K., Yiannoutsos, C. T. &
- 636 Halverson, P. K. How Many SARS-CoV-2–Infected People Require Hospitalization?
- 637 Using Random Sample Testing to Better Inform Preparedness Efforts. J. Public Heal.
- 638 Manag. Pr. 27, 246–250 (2021).
- 42. V, C. L., Huebner, J., Hripcsak, G. & Sabatello, M. Underrepresentation of blind and
- deaf participants in the All of Us Research Program. *Nat. Med.* 29, 2742–2747 (2023).
- 43. Goldstein, B. A., Bhavsar, N. A., Phelan, M. & Pencina, M. J. Controlling for
- 642 Informed Presence Bias Due to the Number of Health Encounters in an Electronic
- 643 Health Record. Am. J. Epidemiology 184, 847–855 (2016).
- 44. Perets, O. et al. Inherent Bias in Electronic Health Records: A Scoping Review of
- 645 Sources of Bias. *medRxiv* 2024.04.09.24305594 (2024)

- 646 doi:10.1101/2024.04.09.24305594.
- 647 45. Tang, J. W. et al. Global epidemiology of non-influenza RNA respiratory viruses:
- 648 data gaps and a growing need for surveillance. *Lancet Infect. Dis.* 17, e320–e326
- 649 (2017).